<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE us-patent-application SYSTEM "us-patent-application-v43-2012-12-04.dtd" [ ]><us-patent-application lang="EN" dtd-version="v4.3 2012-12-04" file="US20140004153A1-20140102.XML" status="PRODUCTION" id="us-patent-application" country="US" date-produced="20131218" date-publ="20140102"><us-bibliographic-data-application lang="EN" country="US"><publication-reference><document-id><country>US</country><doc-number>20140004153</doc-number><kind>A1</kind><date>20140102</date></document-id></publication-reference><application-reference appl-type="utility"><document-id><country>US</country><doc-number>13932649</doc-number><date>20130701</date></document-id></application-reference><us-application-series-code>13</us-application-series-code><classifications-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>G</section><class>01</class><subclass>N</subclass><main-group>33</main-group><subgroup>68</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr></classifications-ipcr><classifications-cpc><main-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>G</section><class>01</class><subclass>N</subclass><main-group>33</main-group><subgroup>6893</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></main-cpc></classifications-cpc><classification-national><country>US</country><main-classification>4242771</main-classification><further-classification>435  611</further-classification></classification-national><invention-title id="d0e43">USE OF SOMATIC MUTATIONS IN THE EXTRACELLULAR DOMAIN OF TRANSMEMBRANE PROTEINS IN A PATIENT'S TUMOR AS IMMUNOGENS FOR ACTIVE HUMORAL IMMUNOTHERAPY OF CANCER</invention-title><us-related-documents><us-provisional-application><document-id><country>US</country><doc-number>61667359</doc-number><date>20120702</date></document-id></us-provisional-application></us-related-documents><us-parties><us-applicants><us-applicant sequence="00" app-type="applicant" designation="us-only" applicant-authority-category="assignee"><addressbook><orgname>LANCELL, L.L.C.</orgname><address><city>SAN DIEGO</city><state>CA</state><country>US</country></address></addressbook><residence><country>US</country></residence></us-applicant></us-applicants><inventors><inventor sequence="00" designation="us-only"><addressbook><last-name>COWING</last-name><first-name>CAROL O</first-name><address><city>DEL MAR</city><state>CA</state><country>US</country></address></addressbook></inventor><inventor sequence="01" designation="us-only"><addressbook><last-name>COWING-ZITRON</last-name><first-name>CHRISTOPHER</first-name><address><city>DEL MAR</city><state>CA</state><country>US</country></address></addressbook></inventor></inventors></us-parties></us-bibliographic-data-application><abstract id="abstract"><p id="p-0001" num="0000">Methods of identifying tumor-specific mutations that can serve as B cell epitopes for the induction of autologous tumor-specific antibodies are disclosed. In some embodiments, the methods include: identifying a tumor-specific mutation in an expressed gene of a subject having cancer; determining that the mutation is in a region of an open reading frame predicted to encode an extracellular domain of a membrane protein; and identifying a corresponding mutant polypeptide encoded by the expressed gene comprising the tumor-specific mutation. Some embodiments relate to a method of inducing a tumor specific immune response in a subject including administering one or more polypeptides identified according to the methods disclosed herein to a subject. Other embodiments relate to pharmaceutical compositions including mutant polypeptide(s).</p></abstract></us-patent-application>